Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01382719 · ClinicalTrials.gov registry record · Phase 2
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
A Phase 2 study, sponsored by Palatin Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 612
- Enrollment target
NCT01382719 is a Phase 2 study that has completed, run by Palatin Technologies. The registered enrollment target is 612 participants.
The verdict
NCT01382719, a Phase 2 study, has completed, sponsored by Palatin Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 612 participants
- Enrollment target
Study Summary
This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide, administered subcutaneously on an as-needed basis under conditions of home use, for the treatment of female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or mixed FSAD/HSDD in premenopausal women.
Interventions
- DRUG bremelanotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 612 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01382719
The ClinicalTrials.gov registry entry for NCT01382719 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 612 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Palatin Technologies, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bremelanotide is the first listed.
NCT01382719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01382719 about?
NCT01382719 is a clinical study titled "Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder". This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide, administered subcutaneously on an as-needed basis under conditions of home use, for the treatment of female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or mixed FSAD/HSDD...
What is the current status of trial NCT01382719?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 612 participants. The study started on 2011-06. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01382719?
The interventions under investigation include: bremelanotide (DRUG).
Who is sponsoring clinical trial NCT01382719?
This trial is sponsored by Palatin Technologies, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.